Tirzepatide
Strong weight loss with a cleaner side effect profile than semaglutide. A dual agonist (GLP-1 + GIP), FDA-approved as Mounjaro / Zepbound.
Tirzepatide: Strong weight loss with a cleaner side effect profile than semaglutide. A dual agonist (GLP-1 + GIP), FDA-approved as Mounjaro / Zepbound. Tirzepatide is the prescription weight-loss drug sold as Mounjaro (diabetes) or Zepbound (weight loss).
Tirzepatide is the prescription weight-loss drug sold as Mounjaro (diabetes) or Zepbound (weight loss). It hits two appetite-control receptors at once. Most users lose 15-20% of body weight over several months. One injection per week.
Body-comp drug. Most natty federations consider any prescription weight-loss drug disqualifying.
FDA-approved drug products containing this substance are available. Compounded versions are not FDA-approved.
Yes, widely prescribed by primary care, endocrinologists, and obesity-medicine specialists.
Wear a CGM the first 14 days.
Verify dose response and watch for hypos at higher doses. A two-week sensor (~$80, OTC, no prescription) tells you more about how YOUR body is responding to Tirzepatide than any protocol guide can. Most users wear one and don't again. The first cycle is the one that matters.
Who it's for
- โUsers who couldn't tolerate semaglutide
- โMetabolic-syndrome adults under provider guidance
- โLong-term weight management
What to expect
- Week 1
Appetite drops. Mild nausea common.
- Week 4
First titration step. ~2-5lb down for most.
- Week 8
Cumulative loss 5-10lb. Side effects taper.
Looking at Tirzepatide? Your next 3 steps
- 1Work out your syringe units
Vial size + BAC water turns into the exact units to draw for Tirzepatide.
Open calculator โ - 2See what to stack & monitor
The companion supplements and the bloodwork worth tracking on this kind of protocol.
Bloodwork guide โ - 3Save it & ask the Coach
A free account gets you Coach questions every day, free; membership saves your stack and makes the Coach stack-aware.
Create free account โ
How it works (mechanism)
Dual agonist hitting GLP-1 receptors (like Semaglutide) AND GIP receptors. The GIP arm adds an additional satiety and insulin-secretion lever, producing stronger weight loss than GLP-1 alone in head to head trials.
Dosing protocol
Stacks well with
Stack essentials
Side effects
When NOT to use
- โ MTC / MEN-2 history
- โ Pancreatitis history
- โ Pregnancy / nursing
Bloodwork to monitor
- โข Lipid panel
- โข ALT/AST
- โข A1C if relevant
Common mistakes
- โข Titrating too fast
- โข Not lifting / eating protein during the cut
- โข Stopping cold turkey without a maintenance plan
What it actually is
A weekly injection that mimics two of the gut hormones your body releases when you eat, GLP-1 and GIP, at once. It is a real approved medicine, sold as Mounjaro for type 2 diabetes and Zepbound for obesity, and it has been through full phase 3 trials rather than being a research chemical. Almost everything sold outside a pharmacy as tirzepatide is a compounded or grey-market copy of that molecule.
GLP-1 and GIP are hormones your intestine releases after a meal. Both prompt the pancreas to release insulin in a glucose-dependent way, and both act on appetite. The slowing of stomach emptying is principally a GLP-1 effect rather than something both hormones do equally. Tirzepatide keeps both signals switched on for about five days at a time, so appetite falls and food stays in the stomach longer. Adding the GIP receptor to GLP-1 is associated with more weight loss than GLP-1 alone; why, exactly, is still being worked out.
Forms, and which is which
Manufacturer-made, identity and sterility assured. Approved formulations include both the auto-injector pen and single-dose and multi-dose vials, so a vial is not automatically a compounded product.
Verdict: The forms where you know what is in it.
Made by compounding pharmacies during the shortage. FDA removed tirzepatide from the shortage list, which narrowed when it may lawfully be compounded at all.
Verdict: Legally narrower than it was, and quality varies by pharmacy.
Sold as 'not for human consumption', reconstituted by the buyer. Identity, purity and sterility are whatever the seller says they are.
Verdict: Carries every quality risk at once.
There is no FDA-approved oral tirzepatide. What is in a product marketed as one cannot be verified, and neither its safety nor its effect has been established.
Verdict: No approved oral form exists.
What it is claimed to do, graded
The SURMOUNT programme is phase 3, placebo-controlled and large. A 2025 NEJM head-to-head against semaglutide found tirzepatide produced greater weight loss. This is as well evidenced as anything in this catalog.
The original approved indication, backed by the SURPASS phase 3 series including placebo and active comparators.
Randomised data supports improvement in MASLD markers, but the trials are smaller and shorter than the weight and glycaemia programme.
Two phase 3 randomised double-blind trials and an FDA indication. The effect is substantially mediated by the weight loss itself, which does not make it less real.
The opposite concern is the live one: a meaningful share of the weight lost on GLP-class drugs is lean mass. Protein intake and resistance training are the countermeasure, not the drug.
Grades describe how much human evidence exists for that specific claim, not whether it will work for you or whether it is safe.
Pros and cons
- โข An approved medicine with phase 3 evidence, which almost nothing else in this catalog can claim
- โข Beat semaglutide head-to-head for weight loss in a 2025 NEJM trial
- โข Weekly dosing, so adherence is easy compared with daily injectables
- โข Real prescribing information exists: known contraindications, known interactions, known monitoring
- โข Gastrointestinal side effects are common and are the usual reason people stop
- โข Weight regain after stopping is the norm rather than the exception, so there has to be a plan for after
- โข Lean mass loss is real and is not addressed by the drug
- โข Grey-market vials are unverified copies, and that is where most non-prescription supply comes from
- โข Expensive without insurance
When to stop
- โข Severe, persistent abdominal pain, especially radiating to the back โ pancreatitis needs assessment, not a dose reduction
- โข A new neck lump, hoarseness or trouble swallowing
- โข Vomiting that stops you keeping fluids down
- โข Signs of gallbladder trouble: right upper abdominal pain, fever, jaundice
- โข New or worsening vision changes โ rapid glucose improvement can transiently worsen diabetic retinopathy
- โข Pregnancy
Interactions
Combined glucose lowering can cause hypoglycaemia. Doses of the other agent usually need reducing, which is a prescriber's job.
Delayed gastric emptying changes how fast oral drugs are absorbed. Labelling calls for caution and monitoring with threshold-dependent and narrow-therapeutic-index drugs, not a general timing workaround.
Labelling advises a non-oral contraceptive or an added barrier method for four weeks after starting and for four weeks after each dose increase.
Labelling does not recommend combining these.
Retained stomach contents despite fasting is a documented aspiration risk. Tell the anaesthetist โ withholding a dose is not established to remove it.
Adds nausea and, alongside reduced food intake, raises hypoglycaemia risk in people also on glucose-lowering drugs.
Not an interaction so much as the missing half of the protocol. This is what limits lean mass loss.
Is this for you?
- โข Adults who meet the approved indications and are working with a prescriber
- โข Anyone weighing this against the other approved options with a clinician, rather than choosing on price
- โข You have a personal or family history of medullary thyroid carcinoma or MEN-2
- โข You have had a serious hypersensitivity reaction to tirzepatide or any ingredient in it
- โข You have severe gastroparesis โ labelling does not recommend use
- โข You are pregnant. A prior episode of pancreatitis is not an automatic exclusion but needs a clinician's assessment rather than a decision made here
The one number
Sources for the claims above
- Outperformed semaglutide for weight loss head-to-head
- Phase 3 efficacy and safety in type 2 diabetes (SURPASS-1)
- Comparative weight loss versus semaglutide in adults with overweight or obesity
Drug & supplement interactions
- โ Insulin and sulfonylureas: dose reduction usually needed
- โ Slows gastric emptying, affects oral medication absorption
- โ Oral contraceptives: switch to non-oral method or add barrier method during initial titration
- โ Warfarin: monitor INR
The Pepdex take
Honest take: we'd run Retatrutide over Tirzepatide if you have access. Tirz works, but the GI side effect intensity isn't talked about enough. Most people who quit bail during the 5-10mg titration because the nausea + reflux is rougher than the marketing implies. If you commit to slow titration and lift heavy through it, the body comp result is genuinely impressive. If you don't lift, you lose 25 lbs of mostly muscle and look worse than when you started.
Community patterns
New to Tirzepatide? Grab the starter checklist.
Drop your email and we'll send the one-page starter checklist beginners actually need first. No account needed.
No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.
Numbers redacted in this preview. Members get the full answer, on their own stack.
Ask the Coach anything about Tirzepatide or your own stack. This is it working.
Trained only on Pepdex content. Does the dose math, flags interactions, knows your stack. Won't push vendors, won't pretend to be a doctor.
Unlock the full Coach, from $4.99/week โFrequently asked
What is Tirzepatide?+
Is Tirzepatide FDA approved?+
Is Tirzepatide legal?+
Is Tirzepatide banned by WADA?+
Are you still natty after taking Tirzepatide?+
Do doctors prescribe Tirzepatide?+
What's the typical dose of Tirzepatide?+
What are the side effects of Tirzepatide?+
How long until Tirzepatide starts working?+
What can you stack with Tirzepatide?+
Where do people get Tirzepatide?+
Tirzepatide vs Semaglutide, which is better?+
Tirzepatide vs Retatrutide, which is better?+
Tirzepatide vs Cagrilintide, which is better?+
Common questions about Tirzepatide
Tracked alongside Tirzepatide
Same goal, different aisle โ each graded on its own evidence in the Pepdex catalog.
More in Fat Loss
The original weight-loss wave, sold as Ozempic / Wegovy. A GLP-1 agonist.
Triple agonist (GLP-1 + GIP + glucagon) from Eli Lilly. In trials it outperforms Tirzepatide for weight loss.
Daily GLP-1 receptor agonist. FDA-approved 2010 (Victoza, T2D) and 2014 (Saxenda, obesity). The first wave of modern GLP-1 weight-loss therapy and direct predecessor to Semaglutide.
An appetite-control shot for weight loss. A long-acting amylin agonist that works on a different pathway than the GLP-1 drugs, often paired with Semaglutide as 'CagriSema' to break GLP-1 plateaus.